2 reports of this reaction
3.8% of all CHILDRENS ACETAMINOPHEN reports
#5 most reported adverse reaction
RESPIRATORY SYNCYTIAL VIRUS INFECTION is the #5 most commonly reported adverse reaction for CHILDRENS ACETAMINOPHEN, manufactured by AARNA USA INC.. There are 2 FDA adverse event reports linking CHILDRENS ACETAMINOPHEN to RESPIRATORY SYNCYTIAL VIRUS INFECTION. This represents approximately 3.8% of all 52 adverse event reports for this drug.
Patients taking CHILDRENS ACETAMINOPHEN who experience respiratory syncytial virus infection should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RESPIRATORY SYNCYTIAL VIRUS INFECTION is moderately reported among CHILDRENS ACETAMINOPHEN users, representing a notable but not dominant share of adverse events.
In addition to respiratory syncytial virus infection, the following adverse reactions have been reported for CHILDRENS ACETAMINOPHEN:
The following drugs have also been linked to respiratory syncytial virus infection in FDA adverse event reports:
RESPIRATORY SYNCYTIAL VIRUS INFECTION has been reported as an adverse event in 2 FDA reports for CHILDRENS ACETAMINOPHEN. This does not prove causation, but indicates an association observed in post-market surveillance data.
RESPIRATORY SYNCYTIAL VIRUS INFECTION accounts for approximately 3.8% of all adverse event reports for CHILDRENS ACETAMINOPHEN, making it a notable side effect.
If you experience respiratory syncytial virus infection while taking CHILDRENS ACETAMINOPHEN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.